Linical Co., Ltd.

Tokyo Stock Exchange 2183.T

Linical Co., Ltd. Price to Earnings Ratio (P/E) on January 28, 2025: 23.06

Linical Co., Ltd. Price to Earnings Ratio (P/E) is 23.06 on January 28, 2025, a 116.53% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Linical Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is 29.05 on July 17, 2024, which is 25.97% above the current Price to Earnings Ratio (P/E).
Linical Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is 7.68 on March 05, 2024, which is -66.68% below the current Price to Earnings Ratio (P/E).
Linical Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is 22.56.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

Tokyo Stock Exchange: 2183.T

Linical Co., Ltd.

CEO	Mr. Kazuhiro Hatano
IPO Date	Oct. 27, 2008
Location	Japan
Headquarters	Shin-Osaka Brick Building
Employees	662
Sector	Health Care
Industries Pharmaceuticals Research & Consulting

Description

Linical Co., Ltd. provides drug development services primarily in the areas of oncology and central nervous system to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in development, regulatory affairs consultation support, and licensing support. It also provides clinical research and development, and contract medical affairs services, including front-end services comprising project management, monitoring, quality control, vendor management, auditing, and clinical research secretariat; and back-end services, which include data management, bio statistical analysis, medical writing, pharmacovigilance, and medical management. The company was incorporated in 2005 and is headquartered in Osaka, Japan.

Key trends

Past 5 years